Why it matters now
China's healthcare market is undergoing a profound transformation driven by national policies aimed at increasing affordability and promoting domestic innovation. The widespread implementation of volume-based procurement is a key lever in this strategy, fundamentally altering how medical devices are purchased and priced. For foreign manufacturers, this represents a significant challenge to established business models and market dominance. Understanding the nuances of these policies is crucial for maintaining competitive presence and adapting to a rapidly evolving regulatory and commercial landscape.
Who is exposed
Foreign medical device manufacturers and multinational pharmaceutical companies are highly exposed to market share erosion and pricing pressure. VBP policies compel significant price reductions in exchange for guaranteed volume, directly impacting revenue and profit margins. This can lead to a loss of market access for certain products, increased competition from domestic players, and the need for substantial adjustments to supply chain and distribution strategies within the Chinese market.
Most relevant for: International Sales Director, Market Access Manager, Strategy Lead
What this Viewpoint covers
- Which device categories are currently targeted by VBP rounds?
- How do VBP rules specifically disadvantage foreign manufacturers?
- What are the typical price reductions observed in VBP tenders?
- Which foreign companies have experienced significant market share shifts?
- How are domestic competitors gaining ground under VBP policies?
Signals to watch
- Announcements of new VBP rounds for specific device categories.
- Changes in VBP bidding rules or eligibility criteria.
- Public statements from Chinese health authorities on procurement strategy.
- Market reports indicating shifts in device sales by origin.
Decisions it supports
- Re-evaluate pricing strategies for products in the Chinese market.
- Adjust product portfolio and R&D investments for future VBP rounds.
- Develop partnerships or localization strategies to mitigate VBP impact.
How it is built
Prepared after your order from dated public sources - such as medical devices & healthcare filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
What is Volume-Based Procurement (VBP)?
VBP is a government-led initiative in China to centralize the bulk purchase of medical products, including devices, to drive down prices. Companies bid for contracts, and those offering the lowest prices for quality products secure significant market volume. It aims to reduce healthcare costs and promote the use of more affordable, often domestically produced, alternatives.
How does VBP impact foreign companies differently?
Foreign companies often face pressure to match the lower prices offered by domestic competitors, which can be challenging given their different cost structures and brand positioning. This can lead to significant revenue and margin compression, and in some cases, a loss of market share to local players who are better positioned to meet the aggressive pricing demands of VBP.
Can foreign companies still succeed in China under VBP?
Success requires strategic adaptation, including localizing production, investing in innovative products not yet subject to VBP, or forming partnerships with domestic entities. Focusing on high-value, specialized segments or services that are less affected by VBP can also provide avenues for growth, requiring a nuanced understanding of the evolving market dynamics.